Archive | August, 2015

What Does It Take to Get a Meeting: The Targeted Outreach Curve

27 Aug

By Lucy Parkinson, Senior Research Manager, LSN

Earlier this month, we covered the benefits of using CRM to organize your fundraising campaign. By logging every contact, you can collect useful data points that will map your campaign’s progress. LSN’s advisory arm, Boston Innovation Capital, logs every call made and every email sent during the course of a fundraising campaign in a CRM system. Using data from a current BIC project, we’ll take a look at what it typically takes for a company to get a meeting.

Using the LSN Investor Platform, BIC generated a list of over 250 investors from around the globe as strong potential fits for the company (a US-based medical device developer). The outreach team designed a concise email pitch and a phone message, and performed outreach to all of the investors on the GTL. Thus far, this outreach has generated meetings with 31 investment and strategic firms. But how many outreach attempts did it take to generate a positive response from each investor? As we store all this information in the campaign Salesforce account, it’s easy for us to dive in there and take a look at the road we’ve travelled.


(Note: the y-axis tracks the number of outreach attempts it took before the investor responded with interest in a meeting. In most cases, it took several more exchanges to pin down a suitable meeting time!)

As the chart demonstrates, if you use a targeted outreach method and contact only investors who are a suitable fit for the opportunity, many investors will respond positively to a well-composed email asking for a meeting. In 14 cases, only one message was required in order for the investor to express an interest in a call. However, if we’d stopped at that one message, our client would have missed out on over half of their total meetings. There are more meetings available in the long tail of persistent outreach than there are in the initial email blast.

Making a second, third, fourth, or more attempts to get in touch with an investor will double your outreach success. Persistence will, of course, also help you filter disinterested investors out of the process; investors can hardly follow up on every opportunity that crosses their desk, and receiving a polite decline allows your campaign to continue more efficiently.

We also found it’s important to vary the outreach. It’s good to use calls to follow up on emails; sometimes the investor saw the original mail, but hasn’t had time to take a deep dive on the opportunity yet, and appreciates the reminder. Leaving a voicemail may also nudge the investor into responding to your email. If you’ve not received a response after several attempts, it can pay to do some research on the person you’re reaching out to; if you check on the firm website and on LinkedIn, you may find that their role has changed and they’re no longer the right person to reach out to with a deal. At this point, you may wish to select a different contact to reach out to.

Additionally it’s often useful to speak to an executive assistant at the firm, who may be knowledgeable about whether you’re reaching out to the right contact for your opportunity, and about the best time and means to reach them. (This is especially useful information during the summer, when an investor might be away from their office for an extended period of time!) Asking the right questions could get you referred internally; once passed to the correct person to assess the opportunity, one typically receives a rapid yes/no decision regarding the meeting request.

Persistence pays off when you’re fundraising. Investors are very busy people, and the most important contacts are sometimes the hardest ones to reach. Even after securing an initial meeting and opening a dialogue with an investor, the follow-up process will be lengthy and frustrating. We hope that this data showing the benefits of outreach persistence will keep your spirits up.

Double Panel Announcement: Medtech and Biotech Angels

27 Aug

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10

Angel investors are some of the earliest and most important allies for entrepreneurs. They supply early stage companies with the much needed capital along with their sector expertise, business acumen, and professional network.

We have seen a growing trend of angels syndicating and participating in larger deals. Angel investment round sizes increased sharply in 2014. The healthcare sector showed the largest growth, where the median angel round reached $2 million, up from $1.57 million in 2013. However each angel group comes with unique membership composition, professional knowledge, and investment focus. It is an often daunting task for a scientist entrepreneur to identify and build relationship with the right angel who will move their new ideas forward.

LSN have gathered the most prominent angel groups in life sciences for two panel sessions to be held simultaneously at RESI Boston: Biotech Angels and Medtech Angels.

The Biotech Angels Panel will be focused on current trends in angel investment in the biopharmaceutical field. The panel will be moderated by Pravin Chaturvedi from TIE Angels, and will hear from:

The Medtech Angels Panel will discuss trends in angel investment in medical technologies including devices, diagnostics, and smart devices. The panel will be moderated by Steve Goodman, Co-Founder at Mid Atlantic Bio Angels, and will hear from:

These sessions will help scientist entrepreneurs to better understand the perspective of an angel. What types of deals are most attractive to each angel? Who is the right group for my technology and how to initiate a dialogue with them? What to expect in the due diligence process? For early stage entrepreneurs considering angel capital, this is an excellent opportunity to meet them face-to-face.

LSN Summer Reading Series, Chapter 14: “Thirty-One Tips for Effective Fundraising”

27 Aug

By Michael Quigley, Director of Research, LSN


To bring LSN’s Life Science Executive’s Fundraising Manifesto toward a close, we provide some motivational advice and tactical reminders to help a fundraising CEO bring their outbound campaign to a successful resolution.

With illustrations and helpful mottos, this ‘cheat sheet’ chapter will help the reader find their way through the fundraising maze in good spirits. From how to stay optimistic during the tough times, to when to stop marketing to investors, this chapter has it covered.

Click here to download/print the chapter PDF

Join us next week for the book’s addendum: “The View Beyond Venture Capital.”

Enjoyed the preview? Buy now from or Barnes & Noble



Hot Life Science Investor Mandate 1: US Based Venture Arm of Chinese Family Office Seeking Preclinical Biologic Opportunities

27 Aug

A private investment group that was founded by a single family out of Hong Kong has four operations based in Shanghai, Beijing, Hong Kong and the US. The US-based venture investment arm is actively seeking new investments in the life sciences across the US, and it occasionally invests in companies in Europe. The group focuses on pre-clinical and clinical stage companies. The investment size will vary and typically it ranges from $2 million -$10 million. The group has no set number of allocations over the next 6-9 months.

In the life sciences the firm is looking for new investments primarily in the biotech therapeutics sector. The group will also look at medical devices and diagnostics opportunities, however, which are not their current focuses. For therapeutics, the group is most interested in biologics. The group invests in a variety of therapeutic areas with a focus on oncology. The group generally invests in pre-clinical stage companies without clinical data, and it also syndicates with other investors for clinical-stage investments.

The group invests in privately held life science companies. The group is generally not interested in commercial-stage companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 2: Large Pharma Company Seeking Partnerships in Cardio, Oncology, Virology and More

27 Aug

A large pharmaceutical company with offices worldwide uses a wide variety of structures in order to engage with innovative early-stage companies, including in-licensing, equity investments, options, collaborations, and acquisitions. The firm is currently looking to form new partnerships with early stage companies worldwide.

The firm is interested in therapeutic assets in the following key disease areas: cardiovascular, fibrosis, immunology, oncology, virology, and genetically-defined diseases. The firm can invest at any stage of development, from very early discovery-stage assets through to marketed products. The firm is open to any technological approach, but is only interested in novel drugs; biosimilars and reformulations are not of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 3: Taiwanese PE Firm Seeking Global Biopharmaceutical, Medtech, and Diagnostic Opportunities

27 Aug

A life science dedicated PE fund of a Taiwanese company engaged in leasing, finance, and investment businesses is currently seeking new opportunities. The fund prefers to invest in early stage companies but is also interested in growth-expansion stage companies. The fund can invest up to USD 30 million or more per company. The fund will focus on companies founded and operated in the Greater China region (60% of fund allocation). The fund is also interested in opportunities from Europe (especially in Switzerland, Germany, and the UK) as well as from the US.

The fund seeks to invest in biopharmaceuticals and medical technologies. In biopharma, the fund focuses on novel drugs, drugs with new indication/dosage form, biosimilar, and API for cancer drug. The fund looks for proprietary drug discovery or development technologies that are able to build a multi-product pipeline and products that address large unmet medical needs. For medical technologies, the firm focuses on molecular IVD test/next-generation sequencing, monitor & diagnostics system, invasive devices, cosmetics/plastic surgery, ICT medical device, and combination products with Greater China market potential. The firm looks for new and innovative technologies that can increase performance, lower cost or open up new business models.

The fund prefers to invest in early stage companies and generally acquires a minority stake in the company. However, the fund does not rule out the possibilities of acquiring a controlling stake if the strategic value exists.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 4: A Foundation for Children’s Health Seeking to Make First Venture Investments

27 Aug

A foundation formed to improve the health and quality of life for children has recently begun looking to make equity investment in early stage companies. The foundation’s programs supports pediatric researchers who work in nonprofit academic, medical or research institutions within the six New England states. The foundation is currently developing a new financial vehicle to make program related investment in commercial companies developing technologies that can improve children’s health. The foundation expects to make 1-2 equity allocations of $200,000 in the current year and is seeking opportunities globally.

The foundation is looking for high impact innovations in children’s health with a special interest in neonatal care and pediatric neurology. The foundation is agnostic to technology sectors. The foundation is interested in single assets as well as platform technology that can be applied to the pediatric field.

The foundation seeks privately held companies with competent management teams with sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email